Can ketamine help with migraines?

Yes, research shows that IV ketamine can significantly reduce pain in chronic and refractory migraines by blocking NMDA receptors and reducing central sensitization. Clinical data shows 66% of patients report 50% or greater improvement, with average pain scores dropping from 7.5 to 3.4 on a 10-point scale.

How does ketamine work differently than migraine medications?

Triptans target serotonin receptors, CGRP inhibitors block pain peptides, and preventive medications work through various other mechanisms. Ketamine addresses the underlying NMDA and glutamate system dysfunction that drives central sensitization — the process where your nervous system gets stuck amplifying pain signals. This fundamentally different mechanism is why ketamine can help patients who have not responded to conventional migraine treatments.

How long do ketamine's effects last for migraines?

About one-third of responders experience sustained relief from their migraines. For the other two-thirds, the effects typically last three to six months before a booster infusion may be needed. Duration of relief can vary depending on migraine severity, frequency, and individual response to treatment.

Is IV ketamine safe for migraine patients?

Yes. IV ketamine has been safely administered for migraines in clinical settings across multiple studies. Side effects are mild and temporary, typically including mild dissociation and possible nausea that resolve shortly after the infusion ends. At Music City Ketamine, Marla Peterson, CRNA, provides anesthesia-level monitoring throughout every session using the same equipment and protocols used in operating rooms.

Do I need a referral from my neurologist?

No referral is required to schedule a consultation or begin treatment at Music City Ketamine. However, we encourage coordination with your existing neurologist and other providers for the best outcomes. Ketamine therapy works alongside your existing care plan, not as a replacement for it.

Ketamine for Migraines: How IV Therapy Targets Chronic Headache Pain

Why Migraines Are More Than “Just a Headache”

Migraines affect approximately 39 million Americans, making them one of the most common neurological conditions in the country. But the numbers only tell part of the story. Anyone who lives with chronic migraines knows they are not simply bad headaches. They are complex neurological events that can involve debilitating pain, nausea, visual disturbances, sensitivity to light and sound, and cognitive disruption that can last hours to days.

Chronic migraine—defined as 15 or more headache days per month—represents a particularly challenging subset. Many patients with chronic migraine have cycled through triptans, CGRP inhibitors, beta-blockers, anticonvulsants, Botox injections, and other preventive strategies without finding adequate relief. When multiple treatments fail, the condition is considered refractory, and the search for alternatives becomes urgent.

What makes refractory migraine so difficult to treat is a process called central sensitization. Over time, the nervous system essentially gets stuck in a state of heightened reactivity. Pain pathways become amplified. Signals that should not register as painful begin to hurt. The brain's pain processing circuitry becomes hyperactive, and each migraine episode reinforces the cycle, making the next one more likely.

This is the same mechanism that ketamine addresses in other chronic pain conditions. And it is the reason researchers began investigating ketamine as a treatment for migraines in the first place.

How Ketamine Works for Migraines

Most migraine medications target specific parts of the migraine cascade. Triptans work on serotonin receptors to constrict blood vessels. CGRP inhibitors block a pain-signaling peptide. Preventive medications like topiramate or propranolol work through various indirect mechanisms. Each of these approaches has value, but none of them addresses the underlying NMDA receptor dysfunction that drives central sensitization.

Ketamine works through a fundamentally different mechanism. As an NMDA receptor antagonist, it directly blocks the glutamate receptors that are responsible for amplifying pain signals in the central nervous system. Glutamate is the brain's primary excitatory neurotransmitter, and in chronic migraine, the NMDA receptors that respond to glutamate become overactive—contributing to the wind-up of pain processing that characterizes central sensitization.

By blocking these receptors, ketamine achieves several things simultaneously:

Reduces central sensitization. Ketamine quiets the hyperactive pain signaling that keeps chronic migraines cycling, effectively resetting the nervous system's pain threshold.
Eliminates allodynia. Allodynia—pain from normally non-painful stimulation like touching the scalp or wearing glasses—is a hallmark of central sensitization in migraine. Clinical studies have shown that IV ketamine can completely abolish allodynia.
Blocks cortical spreading depolarization (CSD). CSD is the slow electrical wave that moves across the brain's cortex during migraine aura. Research suggests ketamine can inhibit this wave, potentially preventing the aura phase and the headache that follows.
Targets the trigeminal nucleus caudalis. This brainstem structure is the key pain relay for migraine signals traveling from the head and face to the brain. Ketamine's NMDA blockade modulates activity in this critical junction.
Promotes neuroplasticity. Beyond acute pain relief, ketamine promotes the formation of new synaptic connections, which may help reset pain processing circuits that have been maladaptively rewired by months or years of chronic migraine.

This combination of effects—acute pain reduction, sensitization reversal, and longer-term neural remodeling—is what makes ketamine a qualitatively different option from other migraine treatments. It is not just another drug targeting a different receptor in the same cascade. It addresses the system-level dysfunction that makes chronic migraines self-perpetuating.

What the Research Shows

The clinical evidence for ketamine in migraine treatment has been growing steadily, and the data is encouraging, particularly for patients with refractory cases.

A 2024 review published in Practical Neurology synthesized the available evidence and reported that 66% of patients treated with IV ketamine for chronic migraine reported 50% or greater improvement in their pain. Even more striking, 33% of patients reported 75% to 100% improvement—a level of response that is rarely seen in refractory migraine populations with any treatment.

Clinical studies measuring pain on a standard 10-point scale have shown average reductions from 7.5 at admission to 3.4 at discharge—a clinically meaningful drop that represents the difference between debilitating pain and manageable discomfort.

Several other findings from the research literature stand out:

In a case series of six patients with refractory chronic migraine, all six showed short-term improvement with IV ketamine infusion.
Every patient presenting with allodynia reported total abolishment of that symptom following IV ketamine treatment—a significant finding given that allodynia is one of the most treatment-resistant features of chronic migraine.
A pediatric study found that 64% of young patients did not have headache recurrence within one month of ketamine treatment, suggesting the effects extend well beyond the infusion period.
Regarding duration of response, the data suggests that approximately one-third of responders maintain sustained relief, while the remaining two-thirds benefit for three to six months before a booster infusion may be needed.

The research is promising. While more large-scale randomized controlled trials are needed, the existing evidence provides a strong rationale for offering IV ketamine to patients whose chronic migraines have not responded to conventional treatments. — Based on Practical Neurology, 2024

It is worth noting that ketamine research for migraines is still earlier-stage compared to its evidence base for chronic pain broadly or treatment-resistant depression. But the mechanism of action is well understood, the safety profile is established, and the clinical results so far have been consistently positive.

Who Might Be a Good Candidate

Ketamine for migraines is not a first-line treatment. It is best suited for patients who have already tried and not adequately responded to conventional migraine therapies. Specifically, good candidates tend to include:

Patients who have not responded to triptans, CGRP inhibitors, Botox, or preventive medications. If you have worked through the standard migraine treatment ladder without finding adequate relief, ketamine offers a genuinely different mechanism of action.
Patients with chronic migraine and features of central sensitization. If you experience allodynia, widespread pain sensitivity, or migraines that seem to trigger each other in an escalating cycle, the NMDA-mediated mechanism of ketamine may be particularly relevant.
Patients who want to avoid opioid-based pain management. Some patients with refractory migraine are prescribed opioids as a last resort, despite the well-documented risks of tolerance, dependence, and medication overuse headache. Ketamine provides potent pain relief through a non-opioid mechanism.
Patients dealing with migraine plus depression or anxiety. Chronic migraine and mood disorders frequently co-occur. Ketamine is one of the few treatments that can meaningfully address both. If your migraines are intertwined with depression or anxiety, the dual benefit may be especially valuable.

What a Migraine-Focused Ketamine Session Looks Like

If you have read about what to expect from a ketamine infusion at Music City Ketamine, the experience for migraine treatment follows the same general framework.

You will be welcomed into a private treatment room at our Cool Springs clinic. The infusion itself lasts 40 to 60 minutes for mental wellness protocols. For chronic pain conditions including migraine, dosing may be adjusted based on your clinical needs and response—your provider will discuss this with you during your consultation.

Marla Peterson, CRNA, administers and monitors every session directly. With over 20 years of anesthesia experience, Marla provides one-on-one care with the same monitoring equipment used in operating rooms—continuous pulse oximetry, blood pressure, and heart rate monitoring throughout. This is the same level of care described in our safety overview.

Walter White and Wilma, our therapy dogs, may stop by to check on you. The environment is intentionally calm and private—far removed from the clinical feel of a hospital infusion center.

Most patients are able to leave 30 to 60 minutes after the session ends. You will need a driver. Many patients return to normal activities the following day.

Important Considerations

We believe in being straightforward about what ketamine can and cannot do for migraines at this stage of the evidence.

Ketamine for migraines is best for refractory cases. It should be considered after other established treatments have been tried. It is not a replacement for your neurologist or your existing migraine management plan.
The research is promising but still developing. While the clinical data is consistently positive, more large-scale randomized controlled trials are needed to establish definitive treatment guidelines for migraine specifically.
Ketamine works alongside existing care, not instead of it. We encourage all migraine patients to maintain their relationship with their neurologist and other providers. Ketamine can be a powerful addition to a comprehensive treatment plan, but it does not replace the need for ongoing neurological care.
Insurance typically does not cover ketamine for migraines. As with other off-label uses, IV ketamine for migraine is a self-pay treatment. At Music City Ketamine, sessions are $475 each. We are transparent about costs upfront so there are no surprises.

The question is not whether ketamine works for migraines—the clinical data says it does for a meaningful percentage of patients. The question is whether it is the right option for your specific situation, given your treatment history, symptom profile, and goals. That is what the consultation is for.